BDR Pharmaceuticals launch Cabozantinib to treat thyroid cancer
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
The net proceeds from the issue will be utilised towards the purchase of machinery, modernising existing units and expansion of its R&D facilities
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
This low-cost and highly reliable technology will help in increasing testing in rural and tribal areas
Incorporating multi-modality image guidance, Ethos therapy provides the ability to personalize the patient's treatment based on their anatomy and position at the time of treatment
Research collaboration covers multiple antibody research programs
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
Subscribe To Our Newsletter & Stay Updated